Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Professor Declan Mc Loughlin

MEDICAL SCHOOL (Psychiatry)
ST PATRICKS HOSPITAL

MEDICAL SCHOOL (Trinity Inst. of Neurosciences (TCIN))


Prof McLoughlin took up the new post of Research Professor of Psychiatry on July 1, 2007. Prior to this I was a Senior Lecturer in the MRC Centre for Neurodegeneration Research at the Institute of Psychiatry, King's College London.
Andrew Harkin, Declan M. McLoughlin, Ketamine and depression: A special kase for kynurenic acid?, Brain, Behavior, and Immunity, 2019, Journal Article, PUBLISHED
Karen M. Ryan, Declan M. McLoughlin, Peripheral blood GILZ mRNA levels in depression and following electroconvulsive therapy, Psychoneuroendocrinology, 2019, Journal Article, PUBLISHED
Read J, Cunliffe S, Jauhar S, McLoughlin DM., Should we stop using electroconvulsive therapy?, BMJ (Clinical research ed.), 364, 2019, pk5233 , Journal Article, PUBLISHED  DOI
Kolshus E, Jelovac A, McLoughlin DM, Bitemporal v. high-dose right unilateral electroconvulsive therapy for depression: a systematic review and meta-analysis of randomized controlled trials - CORRIGENDUM., Psychological medicine, 2018, Journal Article, PUBLISHED
Finnegan M, Bayazit H, Cronin T, Guler K, Galligan T, Karababa FI, McLoughlin DM, Towards International Standards: East Meets West., The journal of ECT, 2018, Journal Article, PUBLISHED
A.P. Allen, M. Naughton, J. Dowling, A. Walsh, R. O'Shea, G. Shorten, L. Scott, D.M. McLoughlin, J.F. Cryan, G. Clarke, T.G. Dinan, Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy, Journal of Psychiatric Research, 100, 2018, p24--32 , Journal Article, PUBLISHED
Martha Finnegan, Stephanie O'Connor, Declan M. McLoughlin, Involuntary and voluntary electroconvulsive therapy: A case-control study, Brain Stimulation, 2018, Journal Article, PUBLISHED
Karen M. Ryan, Ross Dunne, Declan M. McLoughlin, BDNF plasma levels and genotype in depression and the response to electroconvulsive therapy, Brain Stimulation, 2018, Journal Article, PUBLISHED
Declan M McLoughlin, I know not `seems", Australian & New Zealand Journal of Psychiatry, 2018, p000486741877290 , Journal Article, PUBLISHED
Claire L. McGrory, Karen M. Ryan, Erik Kolshus, Martha Finnegan, Declan M. McLoughlin, Peripheral blood SIRT1 mRNA levels in depression and treatment with electroconvulsive therapy, European Neuropsychopharmacology, 28, (9), 2018, p1015--1023 , Journal Article, PUBLISHED
  

Page 1 of 15
Semkovska M, McLoughlin DM , Retrograde autobiographical amnesia following ECT: on the difficulty of finding the baby and clearing murky bathwater, J ECT, 30, (3), 2014, p187 - 188, Journal Article, PUBLISHED
Dunne RA, McLoughlin DM, Physical treatments, Medicine , 40, 2012, p672 - 673, Notes: [ ], Journal Article, PUBLISHED
McLoughlin, DM, Vagus rules still apply., Psychological Medicine, 38, (5), 2008, p625 - 627, Journal Article, PUBLISHED
McLoughlin, DM, Review: repetitive transcranial magnetic stimulation is of unknown effectiveness in people with depression., Evidence-Based Mental Health, 6, (4), 2003, p118 - 118, Journal Article, PUBLISHED
Lovestone S, McLoughlin D., Alzheimer's disease: molecular biology and the quest for a treatment. , Care of the Elderly, 6, 1994, p149-152 , Journal Article, PUBLISHED
Cigeroglu YB, McLoughlin D., Psychotherapy training in Turkey, 1994, - 650-651, Miscellaneous, PUBLISHED

  

I have been investigating the neuronal signalling function of the Alzheimer's disease amyloid precursor protein (APP) and was among the first to identify the FE65 and X11 adaptor proteins as APPbinding partners. To study their functions in vivo, we have made X11 transgenic mice and have demonstrated that the X11s regulate APP processing and reduce cerebral Ab production and deposition. The neuronal X11 proteins are therefore novel therapeutic targets for Alzheimer's disease. I am now leading a research group studying behavioural and electrophysiological effects of X11- mediated reduction in cerebral Ab in an Alzheimer's animal model. On the clinical side, I have also been leading randomised controlled trials of therapeutic neuromodulation techniques (e.g. transcranial magnetic stimulation, electroconvulsive therapy) for neuropsychiatric disorders such as depression and schizophrenia. In St Patrick's Hospital and TCD, we are about to start a 5-year research programme called the EFFECT-Dep Study (enhancing the effectiveness of electroconvulsive therapy in severe depression and understanding its molecular mechanism of action). This programme is supported by a HRB Translational Research Award and its purpose is to improve ECT practice and use it to interrogate the molecular neurobiology of depression. We will carry out a definitive randomised controlled trial comparing bilateral and high-dose unilateral ECT, recruiting 140 patients with severe depression. We will also use an animal model of ECT treatment to characterise changes in global protein expression (i.e. the proteome) in both brain and blood plasma and also carry out similar studies using plasma from depressed patients recruited into the clinical trial. The results of these studies will improve clinical ECT and also help us understand better the molecular mechanism of action of ECT, as well as antidepressant drugs, and lead to identification of candidate peripheral biomarkers for depression, treatment response and depression relapse.